Amgen's Phase 3 Sjögren's win; Novartis' $900M radioligand deal

Plus news about Boehringer, Envisagenics, Ionis, Otsuka, Merck, Lexeo and Mantle. Amgen gets a win from Horizon buyout: Amgen said dazodalibep, a CD40 ligand antagonist, succeeded in a Phase ...